Detailed view for this entity.
“Novo is down today another 5.7% after being down 15% or so the day before when the earnings got released too early.”
“This outlook reflects a positive impact from a $4.2 billion reversal of sale rebate provision related to the 340B drug pricing program in the United States.”
“And so you can start to understand why the stock took a big hit.”
“Novo is back to almost yet the bottom prices that we've seen at the end of 2025. Now of course if you thought that you missed it...”